Evidence map›Paper›PMID 32149481›Full record

ArticleThe journal of pathology. Clinical research2020

Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.

Jiling Wen, Gang Huang, Sheng Liu, Jun Wan, Xuechun Wang, Yini Zhu, William Kaliney, Chao Zhang, Liang Cheng, Xiaofei Wen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pathology. Clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Immune mediated support of metastasis: Implication for bone invasion.Cancer communications (London, England) · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jiling WenDepartment of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR China.
Gang HuangDepartment of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR China.
Sheng LiuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Jun WanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Xuechun WangDepartment of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, USA.
Yini ZhuIntegrated Biomedical Sciences PhD Program, University of Notre Dame, Notre Dame, IN, USA.
William KalineyHarper Cancer Research Institute, University of Notre Dame, Notre Dame, IN, USA.
Chao ZhangTranslational Medical Center for Stem Cell Therapy and Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, PR China.
Liang ChengDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Xiaofei WenDepartment of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR China.
Xin LuDepartment of Biological Sciences, Boler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, USA.ORCID 0000-0002-0284-6478
University of Notre Dame · USIndiana University School of MedicineShanghai East Hospital · CN

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026
$43.4M
NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

Myeloid-derived suppressor cells with polymorphonuclear morphology (PMN-MDSCs) contribute to the progression and immune evasion of prostate cancer. However, the spatial distribution of tumor-infiltrating PMN-MDSCs in primary and metastatic prostate cancer, especially in the context of comparison between the epithelial and stromal compartments of the tumor, has not been characterized. Here, we describe a multicolor immunofluorescence staining study of 90 primary tumors, 37 lymph node metastases (all with matched primary tumors) and 35 bone metastases using archived samples. CD11b

Indexed as

Myeloid-Derived Suppressor CellsAge FactorsBiomarkers, TumorCD11b AntigenCell MovementHumansImmunohistochemistryLewis X AntigenLymphatic MetastasisMaleNeoplasm MetastasisNeutrophilsProstatic NeoplasmsRetrospective StudiesStaining and LabelingTumor MicroenvironmentBiomarkers, TumorCD11b AntigenLewis X Antigenbone metastasisepithelial and stromal areaslymph node metastasismulticolor immunofluorescence stainingpolymorphonuclear MDSCprostate cancertumor microenvironment

Identifiers

PMID32149481
PMCPMC7339199
OpenAlexW3010598561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.